array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2432) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(57) "Regeneron surges after patent case ruling against Viatris" ["snippet_en"]=> string(57) "Regeneron surges after patent case ruling against Viatris" ["url"]=> string(120) "https://www.investing.com/news/stock-market-news/regeneron-surges-after-patent-case-ruling-against-viatris-432SI-3264127" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2023-12-27" ["categories"]=> array(5) { [0]=> string(5) "Legal" [1]=> string(8) "Verdicts" [2]=> string(27) "Business Model & Innovation" [3]=> string(21) "Intellectual Property" [4]=> string(16) "Case Settlements" } } [1]=> array(7) { ["title_en"]=> string(74) "Regeneron Gains After Eye-Drug Patent Victory Over Viatris - BNN Bloomberg" ["snippet_en"]=> string(197) "Regeneron Pharmaceuticals Inc. rose the most in almost two months after a court ruled that the drugmaker’s patent rights were infringed by a cheaper copy of its eye drug developed by Viatris Inc." ["url"]=> string(96) "https://www.bnnbloomberg.ca/regeneron-gains-after-eye-drug-patent-victory-over-viatris-1.2015908" ["image_url"]=> string(78) "https://images.businessradar.com/articles/934626b6-ebe5-4ae4-9ef1-c56964bc6283" ["source"]=> string(15) "bnnbloomberg.ca" ["publication_date"]=> string(10) "2023-12-27" ["categories"]=> array(4) { [0]=> string(8) "Verdicts" [1]=> string(27) "Business Model & Innovation" [2]=> string(5) "Legal" [3]=> string(21) "Intellectual Property" } } [2]=> array(7) { ["title_en"]=> string(64) "Regeneron Gets Judge to Certify Charity Kickback Suit for Appeal" ["snippet_en"]=> string(196) "Regeneron Pharmaceuticals Inc. showed that an appeals court needs to address how closely connected a kickback must be to an allegedly false claim before the a suit against it can proceed to trial." ["url"]=> string(114) "https://news.bloomberglaw.com/federal-contracting/regeneron-gets-judge-to-certify-charity-kickback-suit-for-appeal" ["image_url"]=> string(78) "https://images.businessradar.com/articles/fe557120-750c-45b0-ba4e-e442682cf4fa" ["source"]=> string(16) "bloomberglaw.com" ["publication_date"]=> string(10) "2023-10-26" ["categories"]=> array(4) { [0]=> string(8) "Verdicts" [1]=> string(10) "Litigation" [2]=> string(5) "Legal" [3]=> string(46) "Management of Legal and Regulatory Environment" } } [3]=> array(7) { ["title_en"]=> string(102) "Court Permits Addition Of Inventor To A Patent That Is Subject Of Ongoing Litigation - Patent - Canada" ["snippet_en"]=> string(188) "In Regeneron Pharmaceuticals, Inc v Canada (AG), 2023 FC 768, the Federal Court granted Regeneron's application to add an inventor to its issued patent, which was the subject of pending..." ["url"]=> string(38) "https://www.mondaq.com/Article/1333428" ["image_url"]=> string(78) "https://images.businessradar.com/articles/165ab028-1b40-4167-9a0b-4e2fd5aa5498" ["source"]=> string(10) "mondaq.com" ["publication_date"]=> string(10) "2023-06-23" ["categories"]=> array(3) { [0]=> string(8) "Verdicts" [1]=> string(10) "Litigation" [2]=> string(5) "Legal" } } [4]=> array(7) { ["title_en"]=> string(99) "Breaking: SCOTUS rules unanimously in favor of Sanofi and Regeneron in PCSK9 patent spat with Amgen" ["snippet_en"]=> string(295) "In a closely fought patent battle between PCSK9 rivals Amgen and Sanofi/Regeneron, the Supreme Court ruled unanimously on Thursday that Amgen cannot monopolize the market for any and every antibody that binds to areas of the sweet spot of PCSK9. The win for Sanofi and Regeneron is a setback for" ["url"]=> string(118) "https://endpts.com/breaking-scotus-rules-unanimously-in-favor-of-sanofi-and-regeneron-in-pcsk9-patent-spat-with-amgen/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/ce204c3a-e60c-49a3-8b35-d97303cbe08b" ["source"]=> string(10) "endpts.com" ["publication_date"]=> string(10) "2023-05-18" ["categories"]=> array(4) { [0]=> string(8) "Verdicts" [1]=> string(27) "Business Model & Innovation" [2]=> string(5) "Legal" [3]=> string(11) "US Politics" } } [5]=> array(7) { ["title_en"]=> string(160) "Regeneron V. Mylan BPCIA Aflibercept Litigation Update: Claim Construction Order And Stipulation To Narrow The Case For June 2023 Trial - Patent - United States" ["snippet_en"]=> string(149) "On April 19, the Court issued a claim construction order construing seven terms from the claims of the four patents still being asserted in the case." ["url"]=> string(184) "https://www.mondaq.com/unitedstates/patent/1311310/regeneron-v-mylan-bpcia-aflibercept-litigation-update-claim-construction-order-and-stipulation-to-narrow-the-case-for-june-2023-trial" ["image_url"]=> string(78) "https://images.businessradar.com/articles/a8204e31-8e8d-4a72-8d3f-81e65266a461" ["source"]=> string(10) "mondaq.com" ["publication_date"]=> string(10) "2023-05-04" ["categories"]=> array(3) { [0]=> string(8) "Verdicts" [1]=> string(10) "Litigation" [2]=> string(5) "Legal" } } [6]=> array(7) { ["title_en"]=> string(57) "Amgen-Sanofi patent case divides makers of antibody drugs" ["snippet_en"]=> string(153) "By Patrick Wingrove (Reuters) - Amgen Inc's battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has..." ["url"]=> string(86) "https://wkzo.com/2023/03/27/amgen-sanofi-patent-case-divides-makers-of-antibody-drugs/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/cfdb7ca7-3068-4fd7-950c-1e9a42bf980d" ["source"]=> string(8) "wkzo.com" ["publication_date"]=> string(10) "2023-03-27" ["categories"]=> array(4) { [0]=> string(8) "Verdicts" [1]=> string(10) "Litigation" [2]=> string(5) "Legal" [3]=> string(46) "Management of Legal and Regulatory Environment" } } [7]=> array(7) { ["title_en"]=> string(57) "Amgen-Sanofi patent case divides makers of antibody drugs" ["snippet_en"]=> string(241) "Amgen Inc's battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines." ["url"]=> string(96) "https://www.reuters.com/legal/amgen-sanofi-patent-case-divides-makers-antibody-drugs-2023-03-27/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/087ce6a6-f4b2-4e8e-bbb1-bda5831b72f8" ["source"]=> string(11) "reuters.com" ["publication_date"]=> string(10) "2023-03-27" ["categories"]=> array(10) { [0]=> string(21) "Competitive Behaviour" [1]=> string(46) "Management of Legal and Regulatory Environment" [2]=> string(11) "Competition" [3]=> string(5) "Legal" [4]=> string(11) "Regulations" [5]=> string(15) "Business Ethics" [6]=> string(11) "Legislation" [7]=> string(8) "Verdicts" [8]=> string(21) "Intellectual Property" [9]=> string(10) "Litigation" } } [8]=> array(7) { ["title_en"]=> string(50) "Don’t distort enablement law, Amgen tells SCOTUS" ["snippet_en"]=> string(151) "Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand." ["url"]=> string(94) "https://www.lifesciencesipreview.com/news/don-t-distort-enablement-law-amgen-tells-scotus-5048" ["image_url"]=> string(78) "https://images.businessradar.com/articles/0383aaa7-a77b-4dd3-ae26-0eeb314bf23b" ["source"]=> string(24) "lifesciencesipreview.com" ["publication_date"]=> string(10) "2023-03-09" ["categories"]=> array(5) { [0]=> string(46) "Management of Legal and Regulatory Environment" [1]=> string(5) "Legal" [2]=> string(15) "Business Ethics" [3]=> string(8) "Verdicts" [4]=> string(27) "Business Model & Innovation" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(197) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(193) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(152) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(99) } [4]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(95) } [5]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(83) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(70) } [7]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(61) } [8]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(51) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(50) } [10]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(46) } [11]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(45) } [12]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(35) } [13]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(35) } [14]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(34) } [15]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(33) } [16]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [17]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(33) } [18]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(31) } [19]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(31) } [20]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(31) } [21]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(29) } [22]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(29) } [23]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(28) } [24]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(27) } [25]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(26) } [26]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(24) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(23) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(20) } [29]=> array(2) { ["name"]=> string(8) "Politics" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc